Calcineurin

Subscribe to Selected New Research on Calcineurin

1165 relevant articles (50 outcomes, 127 trials/studies) found for this Bio-Agent

Description: A calcium- and calmodulin-binding protein present in highest concentrations in the central nervous system. Calcineurin is composed of two subunits. A catalytic subunit, calcineurin A, and a regulatory subunit, calcineurin B, with molecular weights of about 60 kDa and 19 kDa, respectively. Calcineurin has been shown to dephosphorylate a number of phosphoproteins including histones, myosin light chain, and the regulatory subunit of cAMP-dependent protein kinase. It is involved in the regulation of signal transduction and is the target of an important class of immunophilin-immunosuppressive drug complexes in T-lymphocytes that act by inhibiting T-cell activation.

Also Known As:

Protein Phosphatase 2B; 2B, Protein Phosphatase; A, Calcineurin; B, Calcineurin; Phosphatase 2B, Protein; Phosphatase-2B, Protein; Calcineurin A; Calcineurin B; PP2B; Protein Phosphatase-2B

Relationship Network

Bio-Agent Context: Research Results

Enzymes and Coenzymes: 1

Enzymes: 24394

Hydrolases: 572

Esterases: 221

Phosphoric Monoester Hydrolases: 861

Phosphoprotein Phosphatases: 283

S cerevisiae CMP2 protein

S cerevisiae CNA1 protein

Experts

1.	Molkentin, Jeffery D: 16 articles (03/2008 - 03/2002)
2.	Wilkins, Benjamin J: 6 articles (10/2004 - 05/2002)
3.	Molkentin, J D: 6 articles (03/2001 - 02/2000)
4.	Olson, Eric N: 5 articles (11/2006 - 01/2003)
5.	Bueno, Orlando F: 5 articles (06/2004 - 03/2002)
6.	Lim, H W: 5 articles (03/2001 - 02/2000)
7.	De Windt, L J: 5 articles (03/2001 - 02/2000)
8.	Bassel-Duby, Rhonda: 4 articles (02/2008 - 03/2002)
9.	Heitman, Joseph: 4 articles (02/2008 - 11/2006)
10.	Hill, Joseph A: 4 articles (09/2006 - 03/2002)

Related Diseases

1.	Atopic Dermatitis (Atopic Eczema) 06/01/2006 - "The introduction of topical calcineurin inhibitors resulted in a significant improvement in the treatment of atopic dermatitis" 01/01/2005 - "In several clinical studies of children and adults with atopic dermatitis, topical calcineurin inhibitors were found to be effective both on the face and the trunk and extremities, in both short- and long-term treatment regimens" 10/01/2004 - "BACKGROUND: In several clinical studies, topical calcineurin inhibitors have been shown to be effective in the treatment of atopic dermatitis (AD)" 11/01/2006 - "SUMMARY OF THE FINDINGS: The data showed that calcineurin inhibitors are efficient in the treatment of mild to severe atopic dermatitis, leading to improvement in symptoms, reduction in number of attacks and need of topical corticotherapy" 05/01/2006 - "New drugs such as the topical calcineurin inhibitors have shown promise in treating mild-to-severe atopic dermatitis" Order ALL the reference details at left...
2.	Infection 01/01/2007 - "helveticus R389 enhanced the gut mucosal immunity by improving the mechanisms that reinforce the epithelial and non-specific barriers and the gut functioning at sites of infection, with an improvement in the expression of the enzyme calcineurin, an important signal in the network that activates the gut immune system" 02/01/2005 - "The present study was designed to characterize pulmonary immune responses following infection with an avirulent temperature-sensitive (ts) mutant, calcineurin A1 (cna1) compared to the pathogenic C" 06/01/2007 - "This Review summarizes our current understanding of calcineurin biology in these fungal species, and its exciting potential role in treating invasive fungal infections." 06/01/2007 - "Harnessing calcineurin as a novel anti-infective agent against invasive fungal infections." 12/29/2006 - "Interestingly, cells deleted for UTR2, CRH11, and CRH12 were, like a calcineurin mutant, avirulent in a mouse model of systemic infection but retained the capacity to colonize target organs (kidneys) as the wild type" Order ALL the reference details at left...
3.	Ischemia 02/01/2004 - "Endotracheal calcineurin inhibition ameliorates injury in an experimental model of lung ischemia-reperfusion." 05/15/1999 - "Several studies have suggested that unknown inhibitory factor(s) and/or reversible changes in calcineurin act to modify enzyme activity after ischemia" 10/01/2008 - "Interestingly, the inhibitors of calcineurin and PP1/PP2A could enhance nNOS phosphorylation at Ser847 site at 1 day of reperfusion after ischemia but not at 6 hr of reperfusion" 09/01/2006 - "Cell injury in response to simulated ischemia-reperfusion was studied following overexpression of active calcineurin" 11/30/2005 - "In cultured rat hippocampal neurons, chemical ischemia (CI) elicited a similar dephosphorylation and translocation of Kv2.1. These events were reversible and were mediated by Ca2+ release from intracellular stores and calcineurin-mediated Kv2.1 dephosphorylation" Order ALL the reference details at left...
4.	Skin Diseases 05/01/2005 - "Calcineurin inhibitors for the treatment of skin disease: how do they work?" 03/01/2005 - "The introduction of calcineurin inhibitors represents a major addition to the armamentarium of drugs available to veterinary clinicians for the management of allergic skin diseases" 03/01/2003 - "Macrolactam derivatives, which inhibit calcineurin activation, may be candidates for antiallergic therapy as they reduce both symptoms of inflammatory skin disease in animal models and mast cell degranulation" 05/01/2003 - "The development of topical calcineurin inhibitors resulted in a significant improvement in the treatment of inflammatory skin diseases such as atopic dermatitis" 10/01/2002 - "The therapeutic efficacy of topical calcineurin inhibitors in atopic eczema have restimulated interest in the mechanism of action of these drugs in skin disease" Order ALL the reference details at left...
5.	Cardiomegaly (Heart Hypertrophy) 11/01/2002 - "Whereas the loss of NFATc4 did not compromise the ability of the myocardium to undergo hypertrophic growth, NFATc3-null mice demonstrated a significant reduction in calcineurin transgene-induced cardiac hypertrophy at 19 days, 26 days, 6 weeks, 8 weeks, and 10 weeks of age" 03/01/2006 - "The activation of the calcineurin-nuclear factor of activated T cells cascade during the development of pressure-overload cardiac hypertrophy has been previously reported in a number of studies" 08/15/2004 - "Gain- and loss-of-function studies in genetically altered mice and in cultured cardiomyocytes have demonstrated the necessity and sufficiency of calcineurin to regulate pathologic cardiac hypertrophy" 04/18/2003 - "The Ca2+-dependent phosphatase calcineurin is an essential mediator of cardiac hypertrophy, and in most but not all studies, calcineurin inhibition attenuated cardiac hypertrophy in vivo" 03/01/2002 - "A critical interpretation is given on studies aimed at analyzing the role of calcineurin in cardiac hypertrophy using systemic immunosuppression" Order ALL the reference details at left...

Related Drugs and Biologics

1.	Sirolimus (Rapamycin)
2.	Cyclosporine (Ciclosporin)
3.	Tacrolimus (Prograf)
4.	Calmodulin (Calcium-Dependent Activator Protein)
5.	pimecrolimus (Elidel)
6.	mycophenolate mofetil (Cellcept)
7.	Adrenal Cortex Hormones (Corticosteroids)
8.	Steroids
9.	Glucocorticoids
10.	Staphylococcal enterotoxin F

Related Therapies and Procedures

1.	Transplantation (Transplant Recipients)
2.	Kidney Transplantation
3.	Transplants (Transplant)
4.	Homologous Transplantation (Allograft)
5.	Organ Transplantation

Best Treatments:
Research Summary Report
on Atopic Dermatitis

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 452 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>